![Zheng Bin Yao](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Zheng Bin Yao
Amministratore Delegato presso
ARRIVENT BIOPHARMA, INC.
Patrimonio netto: 22 M $ in data 30/06/2026
Profilo
Dr. Zheng Bin Yao is an Independent Director at Alumis, Inc., a Chairman & Chief Executive Officer at Arrivent BioPharma, Inc. and an Independent Non-Executive Director at VISEN Pharmaceuticals.
He is on the Board of Directors at Alumis, Inc., VISEN Pharmaceuticals, Immune-Onc Therapeutics, Inc. and NiKang Therapeutics, Inc. Dr. Yao was previously employed as a Chairman, President & Chief Executive Officer by Viela Bio, Inc., an Independent Director by NexImmune, Inc., a Senior Vice President & Head-Immuno-Oncology by MedImmune LLC, a Vice President & Head-Research by Tanox, Inc., a Head-Immuno-Oncology Franchise by AstraZeneca PLC, and a Head-Immunology & Infectious Diseases by Genentech, Inc. He received his graduate degree from Anhui Medical University and a doctorate degree from the University of Iowa.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 21/04/2026 | 613.138 ( 1,32% ) | 21 M $ | 30/06/2026 | |
ALUMIS INC. 0,02% | 30/06/2026 | 27.082 ( 0,02% ) | 762 087 $ | 30/06/2026 |
Posizioni attive di Zheng Bin Yao
| Società | Posizione | Inizio |
|---|---|---|
| ALUMIS INC. | Direttore/Membro del Consiglio | 01/06/2021 |
| ARRIVENT BIOPHARMA, INC. | Amministratore Delegato | 01/06/2021 |
| VISEN PHARMACEUTICALS | Direttore/Membro del Consiglio | 01/04/2021 |
Immune-Onc Therapeutics, Inc.
 Immune-Onc Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells | Direttore/Membro del Consiglio | 01/04/2019 |
NiKang Therapeutics, Inc.
 NiKang Therapeutics, Inc. BiotechnologyHealth Technology Develops small molecule oncology medicines to help patients | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Zheng Bin Yao
| Società | Posizione | Fine |
|---|---|---|
| NEXIMMUNE, INC. | Direttore/Membro del Consiglio | 27/08/2024 |
| VIELA BIO, INC. | Amministratore Delegato | 15/03/2021 |
MedImmune LLC
 MedImmune LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Corporate Officer/Principal | 01/02/2018 |
Tanox, Inc.
 Tanox, Inc. Pharmaceuticals: MajorHealth Technology Develops antibody and pharmaceutical solutions used for the treatment of allergic diseases | Corporate Officer/Principal | 19/10/2007 |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formazione di Zheng Bin Yao
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
67
Relazioni di 1° grado
13
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 13 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
MedImmune LLC
MedImmune LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Develops antibody and pharmaceutical solutions used for the treatment of allergic diseases | Health Technology |
NexImmune, Inc.
 NexImmune, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biotechnology company that develops T cell immunotherapies | Health Technology |
University of Iowa
 University of Iowa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Anhui Medical University
 Anhui Medical University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells | Health Technology |
Viela Bio, Inc.
 Viela Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biotechnology company that develops treatments for inflammation and autoimmune diseases | Health Technology |
NiKang Therapeutics, Inc.
NiKang Therapeutics, Inc. BiotechnologyHealth Technology Develops small molecule oncology medicines to help patients | Health Technology |
Alumis, Inc.
 Alumis, Inc. Pharmaceuticals: MajorHealth Technology Engages in research and development of medicines for autoimmune disorders | Health Technology |
Arrivent BioPharma, Inc.
 Arrivent BioPharma, Inc. Pharmaceuticals: OtherHealth Technology Engages in development and commercialization of cancer medicines | Health Technology |
VISEN Pharmaceuticals
 VISEN Pharmaceuticals Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes paradigm-shifting endocrine therapies | Health Technology |
